Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ: EXEL )

35.00 +0.51 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,854,987
Open 34.37
Bid (Size) 33.03 (1)
Ask (Size) 35.23 (1)
Prev. Close 34.49
Today's Range 34.18 - 35.29
52wk Range 20.14 - 37.59
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bullish Setups
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now. 
Via Talk Markets
Topics Stocks / Equities
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire

Performance

YTD
+3.12%
+3.12%
1 Month
-4.24%
-4.24%
3 Month
+1.39%
+1.39%
6 Month
+31.63%
+31.63%
1 Year
+70.90%
+70.90%

More News

Read More
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
From Exelixis, Inc.
Via Business Wire
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
Via Benzinga
2 Stocks to Buy With Less Than $40
Via The Motley Fool
15 Analysts Have This To Say About Exelixis
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Posts 63.7% Profit Surge
Via The Motley Fool
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL: good value for what you're paying.
Via Chartmill
Earnings Scheduled For February 11, 2025
Via Benzinga
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Exelixis, Inc.
Via Business Wire
Investors should take note of NASDAQ:EXEL, a growth stock that remains attractively priced.
Via Chartmill
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
From Exelixis, Inc.
Via Business Wire
Do Not Get Caught Holding Story Stocks- The Market Is Unforgiving
Via Talk Markets
Topics Stocks / Equities
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.